肺がんリキッドバイオプシー市場規模、シェア、動向分析レポート：サンプルタイプ別、バイオマーカー別、技術別、最終用途別、臨床用途別、製品別、地域別、セグメント予測、2024年～2030年

肺がんリキッドバイオプシー市場の成長と動向：

Grand View Research, Incの最新レポートによると、世界の肺がんリキッドバイオプシー市場規模は、2024年から2030年にかけて13.3％のCAGRで成長し、2030年には23億5,000万米ドルに達すると予測されています。

リキッドバイオプシーは、従来の組織生検に代わる非侵襲性を提供し、肺がんの早期発見を可能にします。診断業界は、正確で包括的な診断ツールを必要とする精密医療に向かっています。リキッドバイオプシーは、個別化された治療計画のための情報を提供する有望なソリューションです。

発見の遅れや死亡率の高さなどの要因により、全生存率は低下しています。タバコの喫煙やタバコへの暴露などの生活習慣は、重大な危険因子の一部であり、世界の肺がん患者全体の約80％に寄与しています。世界保健機関（WHO）によると、2020年には世界人口の22.3％がタバコを消費しており、これは男性の36.7％、女性の7.8％を占める。また、タバコは推定130万人の受動喫煙者を含め、毎年800万人以上の死因となっているとしています。

企業は肺がんをスクリーニングする新しい技術や製品を発売しています。例えば、デルフィ・ダイアグノスティックスは2023年10月に肺がんをスクリーニングする血液検査を発売しました。このような新しい発売を伴う発売の増加は、市場を推進すると予想されます。

肺がんリキッドバイオプシー市場レポートハイライト

• サンプルタイプに基づくと、血液サンプルベースのセグメントが2023年の市場を独占しました。これは、このサンプルタイプの非侵襲性、再現性、リアルタイムモニタリング機能、早期発見、費用対効果に起因します。
• バイオマーカーに基づくと、循環核酸セグメントは、がんが早期段階にある場合でも血液サンプル中の非常に低い濃度で検出できるため、2023年の市場をリードしました。
• 技術別では、多遺伝子並列解析（NGS）分野が2023年の市場を独占しました。
• 肺がんの有病率の増加、ライフスタイルの変化、ヘルスケアの進歩、償還政策の利用可能性などの要因により、2023年の肺がんリキッドバイオプシー市場は北米が支配的でした。
• 例えば、American Cancer Society Journalsによると、2022年には米国で約1,918,030人の新たながん症例が観察され、これにはがん死亡の主な原因である肺がんによる毎日約350人の死亡が含まれています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肺がんリキッドバイオプシー市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 肺がんリキッドバイオプシー市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 肺がんリキッドバイオプシー市場：サンプルタイプの推定・動向分析

• サンプルタイプの市場シェア、2023年と2030年
• セグメントダッシュボード
• 肺がんリキッドバイオプシー市場のサンプルタイプ別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 血液サンプルベース
• その他

第5章 肺がんリキッドバイオプシー市場：バイオマーカーの推定・動向分析

• バイオマーカー市場シェア、2023年と2030年
• セグメントダッシュボード
• バイオマーカーによる肺がんリキッドバイオプシー市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
• 循環核酸
• CTC
• エクソソーム/微小小胞体
• 循環タンパク質

第6章 肺がんリキッドバイオプシー市場：技術推定・動向分析

• テクノロジー市場シェア、2023年と2030年
• セグメントダッシュボード
• 技術展望による肺がんリキッドバイオプシー市場
• 2018年から2030年までの市場規模と予測および動向分析
• 多遺伝子平行分析（NGS）
• 単一遺伝子分析（PCR Microarrays）

第7章 肺がんリキッドバイオプシー市場：最終用途の推定・動向分析

• 最終用途市場シェア、2023年および2030年
• セグメントダッシュボード
• 肺がんリキッドバイオプシー市場：最終用途別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 病院・ラボ
• 専門クリニック
• 学術・研究センター
• その他

第8章 肺がんリキッドバイオプシー市場：臨床用途の推定・動向分析

• 臨床用途市場シェア、2023年および2030年
• セグメントダッシュボード
• 臨床用途展望による肺がんリキッドバイオプシー市場
• 2018年から2030年までの市場規模と予測および動向分析
• 病院・ラボ
• 専門クリニック
• 学術・研究センター
• その他

第9章 肺がんリキッドバイオプシー市場：製品推定・動向分析

• 製品市場シェア、2023年および2030年
• セグメントダッシュボード
• 肺がんリキッドバイオプシー市場：製品別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 機器
• 消費者キット・試薬
• ソフトウェア・サービス

第10章 肺がんリキッドバイオプシー市場：地域推定・動向分析

• 地域別市場シェア、2023年および2030年
• 肺がんリキッドバイオプシー市場の地域別展望
• 2018年から2030年までの市場規模と予測および動向分析
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第11章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
• 企業プロファイル
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • CARDIFF ONCOLOGY, INC.
  • CareDx
  • Eurofins Scientific
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.
  • LungLife AI, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 North America lung cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
• Table 4 North America lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 5 North America lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 6 North America lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 7 North America lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 8 North America lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 9 North America lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 10 U.S. lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 11 U.S. lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 12 U.S. lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 13 U.S. lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 14 U.S. lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 15 U.S. lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 16 Canada lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 17 Canada lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 18 Canada lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 19 Canada lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 20 Canada lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 21 Canada lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 22 Europe lung cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
• Table 23 Europe lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 24 Europe lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 25 Europe lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 26 Europe lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 27 Europe lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 28 Europe lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 29 UK lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 30 UK lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 31 UK lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 32 UK lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 33 UK lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 34 UK lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 35 Germany lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 36 Germany lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 37 Germany lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 38 Germany lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 39 Germany lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 40 Germany lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 41 France lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 42 France lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 43 France lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 44 France lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 45 France lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 46 France lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 47 Italy lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 48 Italy lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 49 Italy lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 50 Italy lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 51 Italy lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 52 Italy lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 53 Spain lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 54 Spain lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 55 Spain lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 56 Spain lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 57 Spain lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 58 Spain lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 59 Denmark lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 60 Denmark lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 61 Denmark lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 62 Denmark lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 63 Denmark lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 64 Denmark lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 65 Sweden lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 66 Sweden lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 67 Sweden lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 68 Sweden lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 69 Sweden lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 70 Sweden lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 71 Norway lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 72 Norway lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 73 Norway lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 74 Norway lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 75 Norway lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 76 Norway lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 77 Asia Pacific lung cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
• Table 78 Asia Pacific lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 79 Asia Pacific lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 80 Asia Pacific lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 81 Asia Pacific lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 82 Asia Pacific lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 83 Asia Pacific lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 84 Japan lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 85 Japan lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 86 Japan lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 87 Japan lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 88 Japan lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 89 Japan lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 90 China lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 91 China lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 92 China lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 93 China lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 94 China lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 95 China lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 96 India lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 97 India lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 98 India lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 99 India lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 100 India lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 101 India lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 102 Thailand lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 103 Thailand lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 104 Thailand lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 105 Thailand lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 106 Thailand lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 107 Thailand lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 108 South Korea lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 109 South Korea lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 110 South Korea lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 111 South Korea lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 112 South Korea lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 113 South Korea lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 114 Australia lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 115 Australia lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 116 Australia lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 117 Australia lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 118 Australia lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 119 Australia lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 120 Latin America lung cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
• Table 121 Latin America lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 122 Latin America lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 123 Latin America lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 124 Latin America lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 125 Latin America lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 126 Latin America lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 127 Brazil lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 128 Brazil lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 129 Brazil lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 130 Brazil lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 131 Brazil lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 132 Brazil lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 133 Mexico lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 134 Mexico lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 135 Mexico lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 136 Mexico lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 137 Mexico lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 138 Mexico lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 139 Argentina lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 140 Argentina lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 141 Argentina lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 142 Argentina lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 143 Argentina lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 144 Argentina lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 145 MEA lung cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
• Table 146 MEA lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 147 MEA lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 148 MEA lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 149 MEA lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 150 MEA lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 151 MEA lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 152 South Africa lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 153 South Africa lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 154 South Africa lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 155 South Africa lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 156 South Africa lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 157 South Africa lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 158 Saudi Arabia lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 159 Saudi Arabia lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 160 Saudi Arabia lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 161 Saudi Arabia lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 162 Saudi Arabia lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 163 Saudi Arabia lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 164 UAE lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 165 UAE lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 166 UAE lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 167 UAE lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 168 UAE lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 169 UAE lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)
• Table 170 Kuwait lung cancer liquid biopsy market, by sample type, 2018 - 2030 (USD Million)
• Table 171 Kuwait lung cancer liquid biopsy market, by biomarker, 2018 - 2030 (USD Million)
• Table 172 Kuwait lung cancer liquid biopsy market, by technology, 2018 - 2030 (USD Million)
• Table 173 Kuwait lung cancer liquid biopsy market, by end-use, 2018 - 2030 (USD Million)
• Table 174 Kuwait lung cancer liquid biopsy market, by clinical application, 2018 - 2030 (USD Million)
• Table 175 Kuwait lung cancer liquid biopsy market, by product, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Lung cancer liquid biopsy market: market outlook
• Fig. 9 Lung cancer liquid Biopsy Market Competitive Insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Lung cancer liquid biopsy market driver impact
• Fig. 14 Lung cancer liquid biopsy market restraint impact
• Fig. 15 Lung cancer liquid biopsy market: Sample type movement analysis
• Fig. 16 Lung cancer liquid biopsy market: Sample type outlook and key takeaways
• Fig. 17 Blood sample-based market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Lung cancer liquid biopsy market: Biomarker movement analysis
• Fig. 20 Lung cancer liquid biopsy market: Biomarker outlook and key takeaways
• Fig. 21 Circulating nucleic acids market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 CTC market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Exosomes/microvesicles market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Circulating proteins market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Lung cancer liquid biopsy market: Technology movement analysis
• Fig. 26 Lung cancer liquid biopsy market: Technology outlook and key takeaways
• Fig. 27 Multi-gene-parallel analysis (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Single gene analysis (PCR Microarrays) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Lung cancer liquid biopsy market: End-use movement analysis
• Fig. 30 Lung cancer liquid biopsy market: End-use outlook and key takeaways
• Fig. 31 Hospitals and laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Specialty clinics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Academic and research centers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Lung cancer liquid biopsy market: Clinical application movement analysis
• Fig. 36 Lung cancer liquid biopsy market: Clinical application outlook and key takeaways
• Fig. 37 Therapy selection market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Treatment monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Early cancer screening market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Recurrence monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Lung cancer liquid biopsy market: Product movement analysis
• Fig. 43 Lung cancer liquid biopsy market: Product outlook and key takeaways
• Fig. 44 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Consumables kits and reagents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Software and services market estimates and forecasts, 2018 - 2030 (USD Million)

Lung Cancer Liquid Biopsy Market Growth & Trends:

The global lung cancer liquid biopsy market size is anticipated to reach USD 2.35 billion by 2030, growing at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling earlier detection of lung cancer. The diagnostics industry is moving towards precision medicine, which requires accurate and comprehensive diagnostic tools. Liquid biopsies offer a promising solution for providing information for personalized treatment plans.

Factors such as late detection and high mortality rates result in a decline in the overall survival rate. Lifestyle habits such as cigarette smoking and tobacco exposure are some of the significant risk factors, contributing to approximately 80% of the total lung cancer cases worldwide. According to the World Health Organization (WHO), in 2020, 22.3% of the world's population consumed tobacco, which constitutes 36.7% of men and 7.8% of the total women. It also states that tobacco causes the deaths of more than 8 million people each year, including an estimated 1.3 million passive smokers.

Companies are launching newer technologies and products to screen lung cancers. For instance, Delfi Diagnostics launched its blood test to screen for lung cancer in October 2023. This increasing number of launches involving newer launches is anticipated to propel the market.

Lung Cancer Liquid Biopsy Market Report Highlights:

• Based on sample type, the blood sample-based segment dominated the market in 2023. This can be attributed to the non-invasive nature, repeatability, real-time monitoring capabilities, early detection, and cost-effectiveness of this sample type.
• Based on biomarker, the circulating nucleic acids segment led the market in 2023 as it can be detected at very low concentrations in blood samples, even when cancer is at an early stage.
• Based on technology, the multi-gene-parallel analysis (NGS) segment dominated the market in 2023.
• North America dominated the market for lung cancer liquid biopsy in 2023, owing to factors such as the increasing prevalence of lung cancer, changes in lifestyles, advancements in healthcare, and availability of reimbursement policies.
• For instance, according to the American Cancer Society Journals, in 2022, approximately 1,918,030 new cancer cases were observed in the U.S., which included approximately 350 deaths each day from lung cancer, the leading cause of cancer death.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Sample Type
  • 1.2.2. Biomarker
  • 1.2.3. Technology
  • 1.2.4. End-use
  • 1.2.5. Clinical Application
  • 1.2.6. Product
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Sample Type Outlook
  • 2.2.2. Biomarker Outlook
  • 2.2.3. Technology Outlook
  • 2.2.4. End-use Outlook
  • 2.2.5. Clinical Application Outlook
  • 2.2.6. Product Outlook
• 2.3. Competitive Insights

Chapter 3. Lung Cancer Liquid Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Lung Cancer Liquid Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Lung Cancer Liquid Biopsy Market: Sample Type Estimates & Trend Analysis

• 4.1. Sample Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Lung Cancer Liquid Biopsy Market by Sample Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Blood Sample Based
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Others
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Lung Cancer Liquid Biopsy Market: Biomarker Estimates & Trend Analysis

• 5.1. Biomarker Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Lung Cancer Liquid Biopsy Market by Biomarker Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Circulating Nucleic Acids
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. CTC
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Exosomes/Microvesicles
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Circulating Proteins
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Lung Cancer Liquid Biopsy Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Lung Cancer Liquid Biopsy Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Multi-gene-parallel Analysis (NGS)
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Single Gene Analysis (PCR Microarrays)
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Lung Cancer Liquid Biopsy Market: End-use Estimates & Trend Analysis

• 7.1. End-use Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Lung Cancer Liquid Biopsy Market by End-use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospitals and Laboratories
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Specialty Clinics
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Academic and Research Centers
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Others
    • 7.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Lung Cancer Liquid Biopsy Market: Clinical Application Estimates & Trend Analysis

• 8.1. Clinical Application Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Lung Cancer Liquid Biopsy Market by Clinical Application Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Therapy Selection
    • 8.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Treatment Monitoring
    • 8.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Early Cancer Screening
    • 8.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Recurrence Monitoring
    • 8.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Others
    • 8.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Lung Cancer Liquid Biopsy Market: Product Estimates & Trend Analysis

• 9.1. Product Market Share, 2023 & 2030
• 9.2. Segment Dashboard
• 9.3. Lung Cancer Liquid Biopsy Market by Product Outlook
• 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 9.4.1. Instruments
    • 9.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Consumables Kits and Reagents
    • 9.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. Software and Services
    • 9.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Lung Cancer Liquid Biopsy Market: Region Estimates & Trend Analysis

• 10.1. Regional Market Share, 2023 & 2030
• 10.2. Lung Cancer Liquid Biopsy Market by Region Outlook
• 10.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
  • 10.3.1. North America
    • 10.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.1.2. U.S.
    • 10.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.1.3. Canada
    • 10.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.2. Europe
    • 10.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.2. UK
    • 10.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.3. Germany
    • 10.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.4. France
    • 10.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.5. Italy
    • 10.3.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.6. Spain
    • 10.3.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.7. Denmark
    • 10.3.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.8. Sweden
    • 10.3.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2.9. Norway
    • 10.3.2.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.3. Asia Pacific
    • 10.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3.2. Japan
    • 10.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3.3. China
    • 10.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3.4. India
    • 10.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3.5. Thailand
    • 10.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3.6. South Korea
    • 10.3.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3.7. Australia
    • 10.3.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.4. Latin America
    • 10.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.4.2. Brazil
    • 10.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.4.3. Mexico
    • 10.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.4.4. Argentina
    • 10.3.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.3.5. Middle East and Africa
    • 10.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.5.2. South Africa
    • 10.3.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.5.3. Saudi Arabia
    • 10.3.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.5.4. UAE
    • 10.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.5.5. Kuwait
    • 10.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. List of key distributors and channel partners
  • 11.3.2. Key customers
  • 11.3.3. Key company heat map analysis, 2023
• 11.4. Company Profiles
  • 11.4.1. Agilent Technologies Inc.
    • 11.4.1.1. Company overview
    • 11.4.1.2. Financial performance
    • 11.4.1.3. Product benchmarking
    • 11.4.1.4. Strategic initiatives
  • 11.4.2. Bio-Rad Laboratories, Inc.
    • 11.4.2.1. Company overview
    • 11.4.2.2. Financial performance
    • 11.4.2.3. Product benchmarking
    • 11.4.2.4. Strategic initiatives
  • 11.4.3. CARDIFF ONCOLOGY, INC.
    • 11.4.3.1. Company overview
    • 11.4.3.2. Financial performance
    • 11.4.3.3. Product benchmarking
    • 11.4.3.4. Strategic initiatives
  • 11.4.4. CareDx
    • 11.4.4.1. Company overview
    • 11.4.4.2. Financial performance
    • 11.4.4.3. Product benchmarking
    • 11.4.4.4. Strategic initiatives
  • 11.4.5. Eurofins Scientific
    • 11.4.5.1. Company overview
    • 11.4.5.2. Financial performance
    • 11.4.5.3. Product benchmarking
    • 11.4.5.4. Strategic initiatives
  • 11.4.6. Exact Sciences Corporation
    • 11.4.6.1. Company overview
    • 11.4.6.2. Financial performance
    • 11.4.6.3. Product benchmarking
    • 11.4.6.4. Strategic initiatives
  • 11.4.7. F. Hoffmann-La Roche Ltd
    • 11.4.7.1. Company overview
    • 11.4.7.2. Financial performance
    • 11.4.7.3. Product benchmarking
    • 11.4.7.4. Strategic initiatives
  • 11.4.8. Guardant Health
    • 11.4.8.1. Company overview
    • 11.4.8.2. Financial performance
    • 11.4.8.3. Product benchmarking
    • 11.4.8.4. Strategic initiatives
  • 11.4.9. Illumina, Inc.
    • 11.4.9.1. Company overview
    • 11.4.9.2. Financial performance
    • 11.4.9.3. Product benchmarking
    • 11.4.9.4. Strategic initiatives
  • 11.4.10. LungLife AI, Inc.
    • 11.4.10.1. Company overview
    • 11.4.10.2. Financial performance
    • 11.4.10.3. Product benchmarking
    • 11.4.10.4. Strategic initiatives
  • 11.4.11. Myriad Genetics, Inc.
    • 11.4.11.1. Company overview
    • 11.4.11.2. Financial performance
    • 11.4.11.3. Product benchmarking
    • 11.4.11.4. Strategic initiatives
  • 11.4.12. Natera, Inc.
    • 11.4.12.1. Company overview
    • 11.4.12.2. Financial performance
    • 11.4.12.3. Product benchmarking
    • 11.4.12.4. Strategic initiatives
  • 11.4.13. QIAGEN
    • 11.4.13.1. Company overview
    • 11.4.13.2. Financial performance
    • 11.4.13.3. Product benchmarking
    • 11.4.13.4. Strategic initiatives
  • 11.4.14. Thermo Fisher Scientific Inc.
    • 11.4.14.1. Company overview
    • 11.4.14.2. Financial performance
    • 11.4.14.3. Product benchmarking
    • 11.4.14.4. Strategic initiatives